European Medicines Agency
Evaluation of Medicines for Human Use

Doc. Ref.: EMEA/111857/2009

ASSESSMENT REPORT

FOR

Fertavid

International Non-proprietary Name: follitropin beta

Procedure No. EMEA/H/C/001042

Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

TABLE OF CONTENTS

1. BACKGROUND INFORMATION ON THE PROCEDURE

1.1 Submission of the dossier

The applicant Schering-Plough Europe submitted on 1 July 2008 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for Fertavid, through the centralised procedure according to Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 22 November 2007.

The legal basis for this application refers to Article 10(c) of Directive 2001/83/EC, as amended – relating to informed consent from a marketing authorisation holder N.V. Organon for an authorised medicinal product Puregon (EU/1/96/008/017-031 and EU/1/96/008/038-041)

Scientific Advice:
The applicant did not seek scientific advice at the CHMP.

Licensing status:
The initial product, Puregon, has been given a Community Marketing Authorisation on 3 May 1996.

The Rapporteur and Co-Rapporteur appointed by the CHMP were:
Rapporteur: Ian Hudson Co-Rapporteur: Patrick Salmon

1.2 Steps taken for the assessment of the product

- The application was received by the EMEA on 2 July 2008.
- The procedure started on 27 July 2008.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 27 August 2008. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 29 August 2008.
- During the meeting on 22-25 September 2008, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 25 September 2008.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 17 December 2008.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 9 January 2009.
- During the meeting on 19-22 January 2009, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Fertavid on 22 January 2009. The applicant provided the letters of undertaking on the follow-up measures to be fulfilled post-authorisation on 14 January 2009.

2. SCIENTIFIC DISCUSSION

2.1 Introduction

This application has been submitted as an informed consent application in accordance with Article 10(c) of Directive 2001/83/EC, as amended.
Therefore, consent from the MAH of the Puregon application, which had been submitted as a full application under Art 8(3) of Directive 2001/83/EC as amended, has been given access to Module 2 to Module 5 of the initial dossier of this authorised product and any subsequent post-marketing procedures submitted, assessed and approved.

As a consequence, quality, safety and efficacy of the Fertavid medicinal product is identical to the up-to-date quality, safety and efficacy profile of Puregon. Information on the scientific discussions can be

found in the Puregon CHMP assessment report and in the European Public Assessment Report (EPAR).

The approved therapeutic indication is: "*In the female:* Fertavid is indicated for the treatment of female infertility in the following clinical situations:
– Anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomifene citrate.
– Controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. *in vitro* fertilisation/embryo transfer (IVF/ET), gamete intra-fallopian transfer (GIFT) and intracytoplasmic sperm injection (ICSI)).
In the male: Deficient spermatogenesis due to hypogonadotrophic hypogonadism."

Treatment with Fertavid should be initiated under the supervision of a physician experienced in the treatment of fertility problems.

2.2 Quality aspects

Since this application is an informed consent of the Puregon application, the quality data in support of the Fertavid application is identical to the up-to-date quality data of the Puregon dossier which have been assessed and approved (including all post-marketing procedures).

2.3 Non-clinical aspects

Since this application is an informed consent of the Puregon application, the non-clinical data in support of the Fertavid application is identical to the up-to-date non-clinical data of the Puregon dossier which have been assessed and approved (including all post-marketing procedures).

The CHMP initially raised a concern with regards to the need for an Environmental Risk Assessment (ERA). However, it was justified by the applicant that as FSH has a low octanol/water partitioning coefficient, the absorption into fresh water organisms is unlikely and CHMP agreed that an ERA is not needed.

2.4 Clinical aspects

Since this application is an informed consent of the Puregon application, the clinical data in support of the Fertavid application is identical to the up-to-date clinical data of the Puregon dossier which have been assessed and approved (including all post-marketing procedures).

2.5 Pharmacovigilance

Detailed description of the Pharmacovigilance system

The CHMP initially raised some concerns regarding the procedures in place for reconciliation of adverse events, quality control and audit in pharmacovigilance. Sufficient information has been provided during the procedure and the CHMP considered that the Pharmacovigilance system, as described by the applicant in version 1.3 of the Detailed Description of the Pharmacovigilance system, fulfils the legislative requirements. However, the applicant committed to develop a SOP or formal procedure for reconciliation of adverse events.

Risk Management Plan

The CHMP did not require the marketing authorisation applicant to submit a risk management plan because the reference product Puregon does not have additional risk minimisation activities beyond providing guidance in the prescribing information.

PSURs

The PSUR cycle of Fertavid will correspond to the one of Puregon and the periodic reports for these two products will be submitted in parallel.

2.6 Overall conclusions, risk/benefit assessment and recommendation

Since this application is an informed consent of the Puregon application, the CHMP considered by consensus that based on the data submitted, the risk-benefit balance of Fertavid was favourable and therefore recommended the granting of the marketing authorisation for the following indication:
"*In the female:*
Fertavid is indicated for the treatment of female infertility in the following clinical situations:
– Anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomifene citrate.
– Controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. *in vitro* fertilisation/embryo transfer (IVF/ET), gamete intra-fallopian transfer (GIFT) and intracytoplasmic sperm injection (ICSI)).

In the male: Deficient spermatogenesis due to hypogonadotrophic hypogonadism."

- User consultation

The package leaflet of Fertavid is identical to that of Puregon which is currently undergoing a readability test. The CHMP accepted the applicant's commitment to update the package leaflet of Fertavid in accordance with that of Puregon after its update following this user consultation.